EUSOP

European Specialization in Oncology Pharmacy (EUSOP)

The European Society of Oncology Pharmacy (ESOP) is proud to be able to announce the first European Certification Program for Oncology Pharmacy (EUSOP) provided by the Academy of the European Society of Oncology Pharmacy.

The 100 hour-program consists e-learnings, an international workshop (Excellence Course for Oncology Pharmacy – ExCOP) and national trainings.

After passing the whole EUSOP program, the title “European Oncology Pharmacist (ESOP)” can be achieved.

If you have already attended oncology trainings in your own country, there might be approval within the 100 hours. This will be checked and approved by the EUSOP accreditation committee. As a result you might not have to attend the complete EUSOP program. A personal Score Card will be send out to every new EUSOP-participant. Former attended courses can be stated in this document.

The full program with a total of 100 hours contains:

  • Basics of Oncology Pharmacy (18 hours)
  • Oncology Pharmacy in practice (12 hours)
  • Clinical Oncology Pharmacy (45 hours)
  • Biologics in Oncology Pharmacy (25 hours)

EUSOP

The program is devided in 50 hours of e-learnings, 12 hours of national training and 38 hours of international training (ExCOP – Excellence Course for Oncology Pharmacy).


Further Information regarding Curriculum Part 4 „Biologics in Oncology Pharmacy“

ESOP certified education about biosimilars
Genetically engineered products were first introduced in 1982 with insulin. Since 2006, imitation products, so-called biosimilars, entered the pharmaceutical market. Biosimilars emerged in the past years with the expiration of the patent period of these drugs. Biosimilars are large, complex molecules that are similar but not identical to their classical pharmaceutical equivalents. Their preparation is laborious and costly, and barriers must be overcome for their approval. Immunogenicity issues are also associated with the use of biosimilars. The safety of biosimilars needs to be carefully and constantly monitored. Nonetheless, biosimilars are a critical element in the cost-effective use of biopharmaceuticals with a benefit both for patients and the healthcare system.

To meet up with today’s needs on biosimilars, ESOP has developed a training program on biosimilars. The program includes information on biosimilars, current guidelines and recommended handling procedures for biosimilars.

Delivery of this program is based on: webinars by professionals in the field; regional lectures at scientific conferences in each participating country; and case discussions. A certificate will be given on completion of the training program.

Learning Objectives

  • Explain the importance of analytical work in the development of biosimilars and regulatory approvals.
  • Descriptions of the concepts of extrapolation of immunogenicity and indications based on the integrity of the evidence
  • To assess the importance of access to pharmacoeconomic and biosimilars in oncology in Europe.
  • Summarise the current and emerging data on oncology monoclonal antibody biosimilars and their potential to provide optimal combination therapy.

The goal of the ESOP certified program on biosimilars is to spread knowledge on the meaningful use of biosimilars. The program can be delivered in the national language of the country being given whilst still retaining the same content.

Target group
This training is aimed at oncology pharmacists interested in advancing their practice on treatment of cancer using biosimilars.

The training is based on 3 pillars:

1. Knowledge transfer through specialist lectures on the Internet completed with knowledge examinations (webinars).
Regional lectures at scientific conferences in each participating country
3. Finally, personal work meetings for the discussion of patient cases and personal exchange with certificate.

Genetically engineered products were first introduced in 1982 with insulin. Since 2006, imitation products, so-called biosimilars, entered the global pharmaceutical market. Biosimilars are large, complex molecules that are similar, but not identical to the originator. Their manufacturing process is complex and costly , and barriers must be overcome for their approval. Immunogenicity issues are also associated with the use of biosimilars. The safety of biosimilars needs to be carefully and constantly monitored. Nonetheless, biosimilars are a critical element in the cost-effective use of biopharmaceuticals with a benefit for both patients and the healthcare systems.

To meet up with today’s needs on biosimilars, ESOP has developed a training program. The program includes information on biosimilars, current guidelines and recommended handling procedures. A certificate will be given upon completion of the training program.

Learning Objectives
The participants should be able to:

– Explain the importance of analytical work in the development of biosimilars and regulatory approvals.
– Descriptions of the concepts of extrapolation of immunogenicity and indications based on the integrity of the evidence.
– Assess the importance of access to biosimilars in oncology in Europe.
– Summarise the current and emerging data on biosimilars used in oncology and their potential to provide optimal combination therapy.

The goal of the ESOP certified program on biosimilars is to spread knowledge on the meaningful use of biosimilars. The program can be delivered in the national language of the country whilst still retaining the same content.

The training is based on:

  1. Knowledge transfer through specialist lectures on the Internet completed with knowledge examinations
    (webinars).
  2. Regional lectures at scientific conferences in each participating country
  3. Personal work meetings for the discussion of patient cases and personal exchange with certificate.
Top